[1]Zahar JR, Timsit JF, Garrouste-Orgeas M, et al. Outcomes in severe sepsis and patients with septic shock: pathogen species and infection sites are not associated with mortality[J]. Crit Care Med, 2011, 39(8): 1886-1895.
[2]Dellinger RP, Levy MM, Rhodes A, et al. Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock, 2012[J]. Intensive Care Med, 2013, 39(2): 165-228.
[3]廖延年,黄骞,黎介寿.晚期糖基化终末产物受体在腹腔感染脓毒症中的研究进展[J].医学研究生学报,2015,28(6):656-660.
[4]刘文飞,朱振新,颜荣林.AMPK/mTOR通路参与脓毒症亮氨酸抵抗的研究进展[J].医学研究生学报,2014,27(12):1311-1314.
[5]Albert SG, Ariyan S, Rather A. The effect of etomidate on adrenal function in critical illness: a systematic review[J]. Intensive Care Med, 2011, 37(6): 901-910.
[6]刘瑜,方放,黄方. 糖皮质激素受体基因多态性与脓毒症临床转归的相关性研究[J]. 东南国防医药,2015, 17(6):575-578.
[7]Angus DC, van der Poll T. Severe sepsis and septic shock[J]. New England J Med, 2013, 369(9): 840-851.
[8]Annane D, Bellissant E, Bollaert PE, et al. Corticosteroids in the treatment of severe sepsis and septic shock in adults: a systematic review[J]. JAMA, 2009, 301(22): 2362-2375.
[9]Keh D, Boehnke T, Weber-Cartens S, et al. Immunologic and hemodynamic effects of “low-dose” hydrocortisone in septic shock: a double-blind, randomized, placebo-controlled, crossover study[J]. Am J Resp Crit Care Mede, 2003, 167(4): 512-520.
[10]盛志勇, 姚咏明. 努力提高脓毒症的认识水平[J]. 感染、炎症、修复, 2003, 4(1): 3.
[11]Levy B, Collin S, Sennoun N, et al. Vascular hyporesponsiveness to vasopressors in septic shock: from bench to bedside[M]. Appl Physiol Intensive Care Med, 2012: 251-261.
[12]Gustot T. Multiple organ failure in sepsis: prognosis and role of systemic inflammatory response[J]. Curr Opin Crit Care, 2011, 17(2): 153-159.
[13]李林, 赵亚伟. APACHEⅡ 评分在外科 ICU 中的应用[J]. 中国危重病急救医学, 2002, 14(5): 308-310.
[14]高戈, 冯喆, 常志刚,等. 2012 国际严重脓毒症及脓毒性休克诊疗指南[J]. 中华危重病急救医学, 2013, 25(8): 501-505.
[15]Mayr FB, Yende S, Angus DC. Epidemiology of severe sepsis[J]. Virulence, 2014, 5(1): 4-11.
[16]马朋林. 认识与挑战: 脓毒症流行病学变化的启示[J]. 解放军医学杂志, 2012, 37(11): 1015-1018.
[17]Kibe S, Adams K, Barlow G. Diagnostic and prognostic biomarkers of sepsis in critical care[J]. J Antimicrob Chemother, 2011, 66(suppl 2): 33-40.
[18]Kang CI, Song JH, Chung DR, et al. Risk factors and pathogenic significance of severe sepsis and septic shock in 2286 patients with gram-negative bacteremia[J]. J Infect, 2011, 62(1): 26-33.
[19]Fry DE. Sepsis, systemic inflammatory response, and multiple organ dysfunction: the mystery continues[J]. Am Surg, 2012, 78(1): 1-8.
[20]Michalaki M, Margeli T, Tsekouras A, et al. Hypothalamic-pituitary-adrenal axis response to the severity of illness in non-critically ill patients: does relative corticosteroid insufficiency exist?[J]. Eur J Endocrinol, 2010, 162(2): 341-347.
[21]Marik PE. Glucocorticoids in sepsis: dissecting facts from fiction[J]. Crit Care, 2011, 15(3): 158-163.
[22]Arabi YM, Aljumah A, Dabbagh O, et al. Low-dose hydrocortisone in patients with cirrhosis and septic shock: a randomized controlled trial[J]. Canadian Med Assoc J, 2010, 182(18): 1971-1977.
[23]Barochia AV, Cui X, Vitberg D, et al. Bundled care for septic shock: an analysis of clinical trials[J]. Crit Care Med, 2010, 38(2): 668.
[24]Stearns-Kurosawa DJ, Osuchowski MF, Valentine C, et al. The pathogenesis of sepsis[J]. Ann Rev Pathol, 2011, 6: 19-48.
[25]Krüttgen A, Rose-John S. Interleukin-6 in sepsis and capillary leakage syndrome[J]. J Interferon Cytokine Res, 2012, 32(2): 60-65.
[26]Whiteley W, Jackson C, Lewis S, et al. Inflammatory markers and poor outcome after stroke: a prospective cohort study and systematic review of interleukin-6[J]. PLoS, 2009, 6(9): 145-151.
[27]Vouloumanou EK, Plessa E, Karageorgopoulos DE, et al. Serum procalcitonin as a diagnostic marker for neonatal sepsis: a systematic review and meta-analysis[J]. Intensive Care Med, 2011, 37(5): 747-762.